CSIMarket
 


Sio Gene Therapies Inc   (SIOX)
Other Ticker:  
 

Sio Gene Therapies Inc 's Working Capital Ratio

SIOX's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Current Liabilities decreased faster than Sio Gene Therapies Inc 's Current Assets, this led to improvement in Sio Gene Therapies Inc 's Working Capital Ratio to 21.97, above Sio Gene Therapies Inc average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Working Capital Ratio than Sio Gene Therapies Inc in third quarter 2022. While Working Capital Ratio total ranking has improved so far during the III Quarter 2022 to 245, from total ranking in the second quarter 2022 at 510.

Explain Working Capital Ratio
How much in Current Assets SIOX´s has?
What is the value of SIOX´s Current Liabilities?


SIOX Working Capital Ratio (Dec 31 2022)
III. Quarter
(Sep 30 2022)
II. Quarter
(Jun 30 2022)
I. Quarter
(Mar 31 2022)
IV. Quarter
(Dec 31 2021)
III. Quarter
Y / Y Current Liabilities Change -85.78 % -53.14 % 20.46 % 19.86 % 69.16 %
Y / Y Current Assets Change -47.52 % -50.67 % -50.28 % -45.79 % -7.17 %
Working Capital Ratio MRQ 21.97 11.13 6.46 5.52 5.95
SIOX's Total Ranking # 245 # 510 # 850 # 948 # 1010
Seq. Current Liabilities Change -55.45 % -47.21 % -29.63 % -14.11 % 46.86 %
Seq. Current Assets Change -12.03 % -9.12 % -17.57 % -20.36 % -17.32 %



Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 41
Healthcare Sector # 65
Overall Market # 245


Working Capital Ratio Statistics
High Average Low
72.47 11.87 1.09
(Jun 30 2015)   (Dec 31 2019)




Financial Statements
Sio Gene Therapies Inc 's Current Liabilities $ 2 Millions Visit SIOX's Balance sheet
Sio Gene Therapies Inc 's Current Assets $ 47 Millions Visit SIOX's Balance sheet
Source of SIOX's Sales Visit SIOX's Sales by Geography


Cumulative Sio Gene Therapies Inc 's Working Capital Ratio

SIOX's Working Capital Ratio for the trailling 12 Months

SIOX Working Capital Ratio

(Dec 31 2022)
III. Quarter
(Sep 30 2022)
II. Quarter
(Jun 30 2022)
I. Quarter
(Mar 31 2022)
IV. Quarter
(Dec 31 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth -85.78 % -53.14 % 20.46 % 19.86 % 69.16 %
Y / Y Current Assets TTM Growth -47.52 % -50.67 % -50.28 % -45.79 % -7.17 %
Working Capital Ratio TTM 7.96 6.52 6.93 8.46 10.26
Total Ranking TTM # 4834 # 4703 # 4695 # 4811 # 361
Seq. Current Liabilities TTM Growth -55.45 % -47.21 % -29.63 % -14.11 % 46.86 %
Seq. Current Assets TTM Growth -12.03 % -9.12 % -17.57 % -20.36 % -17.32 %


On the trailing twelve months basis Current Liabilities decreased faster than Sio Gene Therapies Inc 's average Current Assets, this led to increase in in Sio Gene Therapies Inc 's Working Capital Ratio to 7.96, above SIOX average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 570 other companies have achieved higher Working Capital Ratio than Sio Gene Therapies Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 4703 to 4834.

Explain Working Capital Ratio
How much in Current Assets SIOX´s has?
What is the value of SIOX´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 571
Healthcare Sector # 1185
Within the Market # 4834


trailing twelve months Working Capital Ratio Statistics
High Average Low
12.13 5.47 1.69
(Sep 30 2021)   (Mar 31 2020)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2022 MRQ Current AssetsDec 31 2022 MRQ Current Liabilities
Barinthus Biotherapeutics Plc  56.84 $ 213.041  Millions$ 3.748  Millions
Essa Pharma inc   56.08 $ 164.588  Millions$ 2.935  Millions
Xbiotech Inc   54.07 $ 219.843  Millions$ 4.066  Millions
Third Harmonic Bio Inc   51.80 $ 292.835  Millions$ 5.653  Millions
Ars Pharmaceuticals Inc   51.01 $ 277.700  Millions$ 5.444  Millions
Nuvation Bio Inc   50.70 $ 667.318  Millions$ 13.161  Millions
Briacell Therapeutics Corp   50.62 $ 33.939  Millions$ 0.670  Millions
Tyra Biosciences Inc   45.13 $ 257.288  Millions$ 5.701  Millions
Cocrystal Pharma Inc   41.17 $ 40.178  Millions$ 0.976  Millions
Altimmune Inc   40.14 $ 192.813  Millions$ 4.804  Millions
Dice Therapeutics Inc   38.14 $ 577.762  Millions$ 15.149  Millions
Gh Research Plc  37.07 $ 168.541  Millions$ 4.546  Millions
Aprea Therapeutics Inc   35.78 $ 30.154  Millions$ 0.843  Millions
Atea Pharmaceuticals Inc   35.77 $ 660.922  Millions$ 18.478  Millions
Karuna Therapeutics Inc   34.02 $ 1,154.769  Millions$ 33.946  Millions
Terns Pharmaceuticals Inc   33.68 $ 285.185  Millions$ 8.468  Millions
Merrimack Pharmaceuticals Inc  33.66 $ 19.828  Millions$ 0.589  Millions
Cohbar Inc   31.93 $ 16.219  Millions$ 0.508  Millions
Design Therapeutics Inc   31.10 $ 335.119  Millions$ 10.776  Millions
Prometheus Biosciences Inc   31.04 $ 708.151  Millions$ 22.817  Millions
Ironwood Pharmaceuticals inc   30.58 $ 780.626  Millions$ 25.525  Millions
Cassava Sciences Inc  29.91 $ 211.226  Millions$ 7.063  Millions
Synaptogenix Inc   29.39 $ 38.586  Millions$ 1.313  Millions
Minerva Neurosciences Inc   29.15 $ 40.159  Millions$ 1.378  Millions
Eqrx Inc   28.82 $ 1,428.086  Millions$ 49.546  Millions
Cyteir Therapeutics Inc   28.07 $ 149.209  Millions$ 5.315  Millions
Spruce Biosciences Inc   27.43 $ 83.608  Millions$ 3.048  Millions
Xenon Pharmaceuticals Inc   26.44 $ 600.298  Millions$ 22.702  Millions
Kezar Life Sciences Inc   25.98 $ 285.722  Millions$ 10.997  Millions
Astria Therapeutics inc   25.13 $ 227.690  Millions$ 9.060  Millions

Date modified: 2023-02-15T09:51:09+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com